Skip to main content

Table 1 Demographics and clinical features of study patients

From: A serum protein signature at the time of Uveal Melanoma diagnosis predicts long-term patient survival

 

All

Training

Validation

Excluded

P*

n

83

18

56

9

 

Age at diagnosis, mean (SD)

65 (12)

64 (11)

65 (13)

72 (14)

0.27

Sex, n (%)

    

0.96

  Female

43 (52)

9 (50)

27 (48)

4 (44)

 

  Male

40 (48)

9 (50)

29 (52)

5 (56)

 

Ciliary body involvement, n (%)

    

0.79

  Yes

3 (4)

1 (6)

2 (4)

0 (0)

 

  No

80 (96)

17 (94)

54 (969

9 (100)

 

Tumor eye laterality, n (%)

    

0.04

  Right

49 (59)

15 (83)

28 (50)

6 (67)

 

  Left

34 (41)

3 (17)

28 (50)

3 (33)

 

Extrascleral extension, n (%)

    

0.78

  Yes

1 (1)

0 (0)

1 (2)

0 (0)

 

  No

82 (99)

18 (100)

55 (98)

9 (100)

 

Chief complaint at presentation, n (%)

    

0.18

 Shadow in visual field

10 (12)

1 (6)

8 (14)

1 (11)

 

 Reduced visual acuity

19 (23)

4 (22)

12 (21)

3 (33)

 

 Pain

1 (1)

0 (0)

0 (0)

1 (11)

 

 Floaters

4 (5)

1 (6)

3 (5)

0 (0)

 

 Photopsia

11 (13)

4 (22)

5 (9)

2 (22)

 

 No symptoms

38 (46)

8 (44)

28 (50)

2 (22)

 

Visual acuity at diagnosis, mean LogMAR (SD)

0.5 (0.3)

0.5 (0.3)

0.5 (0.3)

0.6 (0.2)

0.61

Tumor thickness at diagnosis, mean mm (SD)

5.7 (2.6)

5.2 (2.8)

5.6 (2.5)

6.6 (2.9)

0.44

Tumor diameter at diagnosis, mean mm (SD)

10.6 (2.4)

11.0 (2.4)

10.6 (2.4)

11.0 (2.5)

0.80

AJCC T-category at diagnosis, n (%)

    

0.22

 T1a

25 (30)

8 (44)

14 (25)

3 (33)

 

 T1b-d

0 (0)

0 (0)

0 (0)

0 (0)

 

 T2a

40 (48)

6 (33)

32 (57)

2 (22)

 

 T2b-d

0 (0)

0 (0)

0 (0)

0 (0)

 

 T3a

17 (21)

4 (22)

9 (16)

4 (44)

 

 T3b-d

0 (0)

0 (0)

0 (0)

0 (0)

 

 T4a-c

0 (0)

0 (0)

0 (0)

0 (0)

 

 T4e

1 (1)

0 (0)

1 (2)

0 (0)

 

AJCC stage at diagnosis, n (%)

    

0.22

 I

25 (30)

8 (44)

14 (25)

3 (33)

 

 IIA

40 (48)

6 (33)

32 (57)

2 (22)

 

 IIB

17 (21)

4 (22)

9 (16)

4 (44)

 

 IIIA

0 (0)

0 (0)

0 (0)

0 (0)

 

 IIIB

0 (0)

0 (0)

0 (0)

0 (0)

 

 IIIC

1 (1)

0 (0)

1 (2)

0 (0)

 

 IV

0 (0)

0 (0)

0 (0)

0 (0)

 

Primary treatment, n (%)

    

0.43

 Plaque brachytherapy

71 (86)

15 (83)

47 (84)

9 (100)

 

 Enucleation

12 (14)

3 (17)

9 (16)

0 (0)

 

Metastasis, n (%)

    

0.16

 Yes

22 (27)

5 (28)

17 (30)

0 (0)

 

 No

61 (73)

13 (72)

39 (70)

9 (100)

 

Median follow-up for survivors, years (IQR)

22.7 (0.7)

22.6 (0.5)

22.9 (0.7)

22.4 (0.5)

0.69

  1. SD, Standard deviation. AJCC, American Joint Committee on Cancer. IQR, Interquartile Range. *P value for difference between training, validation and excluded patients as determined with one-way ANOVA for continuous variables and chi-square tests for categorical variables.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us